Abstract
AbstractMultiple myeloma (MM) is an osteolytic malignancy that is incurable due to the emergence of treatment resistant disease. Defining how, when and where myeloma cell intrinsic and extrinsic bone microenvironmental mechanisms cause relapse is challenging with current biological approaches. Here, we report a biology-driven spatiotemporal hybrid agent-based model of the MM-bone microenvironment. Results indicate MM intrinsic mechanisms drive the evolution of treatment resistant disease but that the protective effects of bone microenvironment mediated drug resistance (EMDR) significantly enhances the probability and heterogeneity of resistant clones arising under treatment. Further, the model predicts that targeting of EMDR deepens therapy response by eliminating sensitive clones proximal to stroma and bone, a finding supported by in vivo studies. Altogether, our model allows for the study of MM clonal evolution over time in the bone microenvironment and will be beneficial for optimizing treatment efficacy so as to significantly delay disease relapse.
Publisher
Springer Science and Business Media LLC
Reference114 articles.
1. Howlader N. N. A., et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. (2019).
2. Galson, D. L., Silbermann, R. & Roodman, G. D. Mechanisms of multiple myeloma bone disease. Bonekey Rep. 1, 135 (2012).
3. Roodman, G. D. Pathogenesis of myeloma bone disease. J. Cell Biochem 109, 283–291 (2010).
4. Cowan, A. J. et al. Diagnosis and Management of Multiple Myeloma: A review. JAMA 327, 464–477 (2022).
5. Abdi, J., Chen, G. & Chang, H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget 4, 2186–2207 (2013).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献